Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Review ArticleReview

Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis

Beverley Shea, Michael V. Swinden, Elizabeth Tanjong Ghogomu, Zulma Ortiz, Wanruchada Katchamart, Tamara Rader, Claire Bombardier, George A. Wells and Peter Tugwell
The Journal of Rheumatology June 2014, 41 (6) 1049-1060; DOI: https://doi.org/10.3899/jrheum.130738
Beverley Shea
From the Bruyère Research Institute (BRI); Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada; Epidemiological Research Center, National Academy of Medicine, Buenos Aires, Argentina; Rheumatology Division, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Cochrane Musculoskeletal Group, Ottawa; Institute for Work and Health, Toronto; Department of Epidemiology and Community Medicine, and the Department of Medicine, Faculty of Medicine, University of Ottawa; Ottawa Hospital Research Institute, Clinical Epidemiology Program; Institute of Population Health and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bevshea@uottawa.ca
Michael V. Swinden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Tanjong Ghogomu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zulma Ortiz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanruchada Katchamart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamara Rader
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Bombardier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George A. Wells
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Tugwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To perform a systematic review of the benefits and harms of folic acid and folinic acid in reducing the mucosal, gastrointestinal, hepatic, and hematologic side effects of methotrexate (MTX); and to assess whether folic or folinic acid supplementation has any effect on MTX benefit.

Methods. We searched the Cochrane Library, MEDLINE, EMBASE, and US National Institutes of Health clinical trials registry from inception to March 2012. We selected all double-blind, randomized, placebo-controlled clinical trials in which adult patients with rheumatoid arthritis (RA) were treated with MTX (dose ≤ 25 mg/week) concurrently with folate supplementation. We included only trials using low-dose folic or folinic acid (a starting dose of ≤ 7 mg weekly) because the high dose is no longer recommended or used. Data were extracted from the trials, and the trials were independently assessed for risk of bias using a predetermined set of criteria.

Results. Six trials with 624 patients were eligible for inclusion. Most studies had low or unclear risk of bias for key domains. The quality of the evidence was rated as “moderate” for each outcome as assessed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group, with the exception of hematologic side effects, which were rated as “low.” There was no significant heterogeneity between trials, including where folic acid and folinic acid studies were pooled. For patients supplemented with any form of exogenous folate (either folic or folinic acid) while receiving MTX therapy for RA, a 26% relative (9% absolute) risk reduction was seen for the incidence of gastrointestinal side effects such as nausea, vomiting, or abdominal pain (RR 0.74, 95% CI 0.59 to 0.92; p = 0.008). Folic and folinic acid also appear to be protective against abnormal serum transaminase elevation caused by MTX, with a 76.9% relative (16% absolute) risk reduction (RR 0.23, 95% CI 0.15 to 0.34; p < 0.00001), as well as reducing patient withdrawal from MTX for any reason [60.8% relative (15.2% absolute) risk reduction, RR 0.39, 95% CI 0.28 to 0.53; p < 0.00001].

Conclusion. The results support a protective effect of supplementation with either folic or folinic acid for patients with RA during treatment with MTX. There was a clinically important significant reduction shown in the incidence of GI side effects and hepatic dysfunction (as measured by elevated serum transaminase levels), as well as a clinically important significant reduction in discontinuation of MTX treatment for any reason.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • COCHRANE REVIEW
  • FOLIC ACID
  • FOLINIC ACID

Methotrexate (MTX) is an antimetabolite with an antagonistic effect on folic acid metabolism. Although its exact mechanism of action in rheumatoid arthritis (RA) is uncertain, it has become the first-line drug of choice1.

Three metaanalyses2,3,4 estimate that a third of the patients show major improvement. However, toxicity does prevent many patients from obtaining benefit from the drug. It has been reported that mild toxicity occurs in about 60% of patients, and roughly 7% to 30% of patients discontinue MTX therapy within the first year of treatment because of toxicity1,5.

Folic acid (also known as vitamin B9) has demonstrated health benefits in a variety of areas. Folinic acid (5-formyl tetrahydrofolate) is one active form in the group of vitamins known as folates. In contrast to folic acid (which is a synthetic form of folate), folinic acid is found naturally in foods. In the body, folinic acid can be converted into any of the other active forms of folate.

Folate deficiency occurs frequently in patients with RA, and folate stores are further decreased in patients with RA who receive MTX6. Gastrointestinal (GI) and hematologic side effects have been related to folate deficiency. There has been concern that high doses of folate supplementation may reduce the efficacy of, and therefore benefit seen with, MTX if the antirheumatic effects are also mediated through folate antagonism7,8,9. The aim of this systematic review was to determine the effect of low doses of folic acid and folinic acid in reducing GI symptoms, hepatic (liver) toxicity, and hematologic side effects of low-dose MTX in patients with RA, and to determine whether folate supplementation with folic acid or folinic acid reduces the anti-arthritis benefit of MTX therapy.

MATERIALS AND METHODS

Types of studies, participants, and interventions

We included all double-blind, randomized, placebo-controlled clinical trials comparing low doses of MTX (≤ 25 mg/week) concurrently with low-dose folate supplementation (either folic or folinic acid), with a starting dose ≤ 7 mg/week in patients older than 18 years, fulfilling the American College of Rheumatology criteria for RA10.

Outcome measures

Major outcomes included GI symptoms (such as nausea, vomiting, or abdominal pain), mouth ulcers (stomatitis), liver toxicity (as measured by raised serum transaminases), hematologic side effects (anemia or cytopenia), and discontinuation of MTX therapy. Minor outcomes included alteration of the beneficial effect of MTX (loss of efficacy) as measured by any of the following: swollen joint count (SJC), tender joint count (TJC), pain, disability score, grip strength, patient global assessment, and physician global assessment.

Search methods for identification of studies

We searched the following electronic databases, unrestricted by language: Cochrane Library Issue 2 of 12, February 2012 (by Wiley), MEDLINE (through OVID 1946–March 2, 2012), and EMBASE (through OVID 1947–February Week 4, 2012). Reports of ongoing trials were searched in the US National Institutes of Health trial registry, ClinicalTrials.Gov (www.clincaltrials.gov). Reference lists from related publications and abstracts of selected rheumatology meetings were scanned for possible inclusion.

The MEDLINE search strategy combined the subject search with the Cochrane highly sensitive search strategy for identifying reports of randomized controlled trials (RCT)11, and was adapted for the other databases. Full search strategies are available on request.

Following an a priori protocol, at least 2 review authors (BS, ZO, WK, MS, TR) independently screened all titles or abstracts generated by the searches for potentially relevant studies. We assessed the full-length articles of the selected titles or abstracts for eligibility. We resolved disagreements by consensus or third-party adjudication.

Data extraction and management

Data were independently extracted by 4 authors (ZO, BS, WK, MS). Folate supplementation was considered as “the administration of folic or folinic acid at any time with respect to MTX.” The GI effects were combined (where possible). The incidence of stomatitis, as well as the incidence of abnormal serum liver enzymes, was analyzed independently. The following hematologic side effects were included, if reported: cytopenia, macrocytosis, or pancytopenia.

To assess changes in disease activity, the following measurements were considered a priori and ultimately included in the efficacy analysis: SJC, TJC, pain, disability score, grip strength, patient global assessment, and physician global assessment. A starting dose of ≤ 7 mg/wk folic or folinic acid was used as a cutoff value for studies to be included in the analysis. Worldwide guidelines currently support co-administration of folic acid with MTX, and where a dose value is suggested, it usually falls in the range of 0.5 to 2 mg daily12,13,14,15.

Assessment of risk of bias (ROB) in included studies

Assessment of ROB was undertaken for each included study using the Cochrane Collaboration’s ROB tool16. The following 7 key domains were assessed: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and “other issues” (comparability of treatment and control group at entry, and appropriateness of duration of surveillance). Pairs of review authors judged the key domains as either “high risk,” “low risk,” or “unclear” ROB. In cases of disagreement, the decision was made by consensus.

Statistical analysis

For each trial, risk ratio (RR) and the 95% CI were calculated for dichotomous outcomes. Mean differences and 95% CI were calculated for continuous outcomes. If the scale for each assessment varied among the studies, we calculated a standardized mean difference based on end-of-trial results. If the SD of the change scores were not available we used the SD of the baseline score for each group. If we noticed missing data during data extraction, we attempted to contact the original investigators of the study to request the required information.

Heterogeneity between comparable trials was tested using a standard chi-square test and considered statistically significant at p < 0.10; after due consideration of the value of the I2 statistic, a value > 50% may indicate substantial heterogeneity. If there were sufficient studies (at least 10) it was intended to assess the possibility of publication bias with funnel plots.

Data synthesis

Where appropriate, results of comparable groups of trials were pooled using the fixed-effect model, and 95% CI were calculated. If heterogeneity existed between studies, a random-effects model was used. Since folic and folinic acid do not act at the same point on the folate pathway, they were analyzed separately as well as together. Metaanalysis was facilitated by RevMan 5 software.

Grading of evidence and summary of findings tables

Major outcomes (including benefits and adverse events) were presented in summary of findings tables, which provide information on the quality of evidence and the magnitude of the intervention effect, as well as a summary of the main outcome data17. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group approach was used to assess the quality of evidence per outcome (high, moderate, low, and very low) as outlined in the Cochrane Handbook for Systematic Reviews of Interventions18.

RESULTS

We initially screened 421 references, from which 15 papers in total were selected for full text appraisal. Six RCT19,20,21,22,23,24 met the eligibility criteria (Figure 1). The other 9 (2 abstracts and 7 articles) were excluded. All RCT included in the analysis assessed hematologic side effects with a complete blood count including platelet count. Some trials also measured mean corpuscular volume. Three of 6 included trials did not report number of patients with hematologic side effects, mean values, or measures of variance and could not be included in the analysis. Overall, the included trials reported 624 participants, of whom 385 were treated with either folinic (211 participants) or folic acid (174 participants). The study flow diagram is given in Figure 2 and characteristics of included studies in Table 1.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Methodological quality summary of included studies. +: low risk of bias; –: high risk of bias; ?: unclear risk of bias.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Study flow diagram.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of included studies of patients with rheumatoid arthritis for more than 18 years.

Effects of interventions

There was no evidence of heterogeneity between included trials. The results from the random-effects model were not substantively different from the fixed-effect model.

Folic acid versus placebo

An 81% relative (16.8% absolute) reduction in risk was observed for the incidence of abnormal serum transaminase levels (RR 0.19, 95% CI 0.10 to 0.36; p ≤ 0.00001), and there was a statistically significant decrease in the number of people who dropped out of the studies for any reason while taking folic acid (−14.2% absolute difference; RR 0.43, 95% CI 0.29 to 0.64; p ≤ 0.0001). A 24% relative (8.1% absolute) reduction was seen for the risk of developing GI side effects such as nausea, vomiting, or abdominal pain, although this failed to reach statistical significance. A trend toward a reduction in the incidence of stomatitis (mouth sores) was seen; however, this also failed to reach statistical significance. Table 2 provides a detailed summary of findings, including the quality of evidence. Figures 3A and 3B show the pooled data based on liver toxicity and total withdrawals when taking folic acid as compared to placebo.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

A. Liver toxicity (folic acid vs placebo). B. Total withdrawals (folic acid vs placebo).

View this table:
  • View inline
  • View popup
Table 2.

Summary of findings: folic acid compared to placebo for reducing side effects in patients receiving methotrexate (MTX) for rheumatoid arthritis.

Folinic acid versus placebo

A 73% relative (15.2% absolute) reduction in risk was observed for the incidence of abnormal serum transaminase levels (RR 0.27, 95% CI 0.16 to 0.44; p ≤ 0.00001), and there was a statistically significant decrease in the number of people who dropped out of the studies for any reason while taking folinic acid (−16.2% absolute difference; RR 0.35, 95% CI 0.23 to 0.53; p ≤ 0.00001). A 22% relative (7.6% absolute) reduction was seen for the risk of developing GI side effects such as nausea, vomiting, or abdominal pain. Similarly, a trend toward a reduction in the incidence of stomatitis (mouth sores) was seen. However, both failed to reach statistical significance. It was not possible to draw meaningful conclusions on the effect of folic or folinic acid on hematologic side effects of MTX because of the small numbers of events and poor reporting of this outcome in included trials. Table 3 provides a detailed summary of findings, including the quality of evidence. Figures 4A and 4B show the pooled data based on liver toxicity and total withdrawals when taking folinic acid as compared to placebo.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

A. Liver toxicity (folinic acid vs placebo). B. Total withdrawals (folinic acid vs placebo).

View this table:
  • View inline
  • View popup
Table 3.

Folinic acid compared to placebo for reducing side effects in patients receiving methotrexate (MTX) for rheumatoid arthritis.

Effect of folic or folinic acid on disease activity (efficacy of MTX)

No statistically significant difference in disease activity (i.e., no statistically significant lowering of the effectiveness of the MTX to treat RA) was observed between placebo and folic or folinic acid at low dosages. There was a weak signal for an increased number of tender joints in patients treated with folic acid (+2.46 swollen joints per patient, 95% CI −6.08 to 11.00; p = 0.61), and both tender and swollen joints for folinic acid (+1.13 tender joints per patient, 95% CI −4.25 to 6.51; p = 0.68), and +1.72 swollen joints per patient (95% CI −3.47 to 6.92; p = 0.52); however, the wide CI suggest that this is likely due to chance. The mean differences in disease activity (SJC and TJC, patient global assessment) between placebo and folate supplementation were analyzed. There was no evidence of a reduction in the mean differences in disease activity (SJC and TJC, patient global assessment) in the folate supplementation groups compared to placebo.

Folic acid or folinic acid versus placebo

When studies using either folic acid or folinic acid were pooled, the results were similar to the analyses of the individual agents versus placebo. Table 4 provides a detailed summary of findings, including the quality of evidence. Figures 5A, 5B, and 5C show the pooled data for nausea, liver toxicity, and total withdrawals when taking either folic acid or folinic acid compared to placebo.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

A. Nausea/gastrointestinal upset (folic or folinic acid vs placebo). B. Liver toxicity (folic or folinic acid vs placebo). C. Total withdrawals (folic or folinic acid vs placebo).

View this table:
  • View inline
  • View popup
Table 4.

Summary of findings: folic or folinic acid (any) compared to placebo for reducing side effects in patients receiving methotrexate (MTX) for rheumatoid arthritis.

Publication bias

A funnel plot to assess publication bias was not provided because there were not enough included studies to conduct this type of analysis.

DISCUSSION

The results support the protective effect of folic or folinic supplementation in patients with RA during treatment with MTX. There was a clinically important and statistically significant reduction in the incidence of abnormal transaminase elevation as well as a clinically important and statistically significant reduction in discontinuation of MTX treatment for any reason in the population studied. A trend toward a reduction in GI side effects and stomatitis was demonstrated, and although this did not reach statistical significance the concurrent statistically significant reduction in discontinuation of MTX treatment for any reason may indicate that the decrease in these side effects was greatest where the side effects were severe enough to result in MTX withdrawal. Although the analysis of hematologic side effects was made difficult by small numbers of events and the outcome being poorly reported in included studies, pooled trials reported no statistically significant differences between patients with RA who received folate supplementation or placebo. The incidence of clinically important cytopenia in patients treated with low dose MTX is estimated to be < 1%25, and therefore the size of a trial designed to detect any differences would be enormous.

Overall completeness and applicability of evidence

Sample size could potentially be a confounding variable because only 1 folinic acid study entered more than 40 patients per group. Interestingly, it appears that the benefit shown was greater for trials with higher numbers of patients and overall higher quality. Several authors26,27 have reported that the inverse is usually true with lower-quality studies showing greater benefits, suggesting biases from poor design. The finding of a trend in the opposite direction in this metaanalysis is reassuring and indicates the likely validity of the reduction of side effects from folate co-administration.

A concern with metaanalysis is the potential existence of publication bias. It is possible that some trials have been completed that found no benefit of folic or folinic acid supplementation. It is difficult to be more definitive about publication bias in this review but we feel it is unlikely that we would be unaware of negative studies of sufficient size to eliminate the benefit seen in this metaanalysis.

Three studies (excluded from our analysis) have suggested that high-dose folinic acid supplementation may reduce the beneficial effects of MTX on RA7,8,9. In a previous version of this review (where these trials were included) there was a difference observed for high-dose folinic acid, which may have suggested a decrease in benefit of the MTX on the arthritis (an isolated increase in the number of tender joints but not in other clinical variables such as patient global assessment). These results were mostly driven by the study by Joyce, et al8 and in our view are still inconclusive. We analyzed the effect of adding these studies back into our metaanalysis, and even when these studies were included the overall results did not show a statistically significant decrease in MTX efficacy. There are no studies that suggest folic acid may alter the efficacy of MTX, despite a folic acid to MTX ratio in some trials higher than the folinic acid to MTX ratio used in the study by Joyce, et al8, a finding that suggested a decrease in MTX efficacy. We did not find any major differences in disease activity between placebo and folic acid at low dosages. It is possible that the timing of administration of folinic acid and MTX, as well as the folinic acid to MTX ratio, may alter the efficacy of MTX, and it should be noted that this question was not possible to include in the design of this review.

Our results support the protective effects of low-dose folate supplementation in reducing GI and hepatic side effects of MTX in patients with RA. This is consistent with the recommendations by some authors22,24,28,29, as well as current prescribing guidelines. Deciding which of the 2 forms of folate supplementation should be recommended is more difficult. Experts have differing recommendations, often acknowledging that there is insufficient evidence for advising the use of one compound over the other5,24,26,27,30.

There is no evidence to date of a significant difference between folic or folinic acid. The results in this metaanalysis were less impressive for folinic acid, but 4 of the 5 studies had small sample sizes, and the larger study by Shiroky, et al22 did show a benefit. Given both the efficacy of folic acid in reducing MTX side effects and its low cost compared with folinic acid, the use of folic acid is likely to be the more cost-effective therapy. For folinic acid to be considered cost-effective it must be proven more effective than folic acid at reducing MTX side effects.

One study31 examined in detail the economics of folate supplementation in patients with RA and concluded that, aside from the differences in cost between folic and folinic acid, potentially the largest influence on overall treatment costs relates to the increased drug survival seen with either agent. If folate supplements can help patients tolerate MTX longer, it may delay or prevent a change in treatment to a far more expensive biologic agent. It is unclear whether all patients taking MTX, or only those with side effects, should receive folate supplementation. Our systematic review cannot address this issue. Most guidelines and texts recommend folate be given to all patients receiving MTX. Yet the effects of folic or folinic acid on the development of liver disease are unknown. It has been suggested that supplementation may have a protective effect on the development of liver disease, in which case universal administration could perhaps be considered.

Supplementation with folic or folinic acid in patients with RA who are taking MTX provides a reduction in the incidence of abnormal liver function tests and a reduction in overall withdrawal from treatment. There is also a trend toward a reduction in the incidence of GI side effects and stomatitis. The results of our review do not suggest any clear clinical advantage of one form of folate over the other.

Quality of the evidence

A major problem in synthesizing evidence is the lack of uniformity in outcome measures. All studies described themselves as randomized but some did not give details of how the randomization sequence was generated and what precautions were taken in relation to concealment of allocation. We encourage investigators to describe fully the numbers and flow of patients by treatment group throughout the trial and to clearly report the reasons for dropouts for each group. The studies were small, with few events. This metaanalysis was hampered by lack of uniformity in the way these items were reported.

Potential biases in the review process

The review was restricted to RCT; we excluded clinical controlled trials, thus limiting the potential for bias.

Our results support the protective effect of low doses of folic or folinic acid supplementation in reducing GI and liver side effects of MTX in patients with RA as well as in reducing patient discontinuation of MTX therapy. A multicenter RCT comparing both folate compounds and including an economic analysis may be necessary to adequately assess potential differences between the drugs.

Acknowledgment

We acknowledge Maria E. Suarez-Almazor and David Moher for their contribution to the original systematic review. The authors also acknowledge Alicia White for preparing the retrospective risk-of-bias tables and the original summary of findings tables, and Jessie McGowan and Margaret Sampson for preparing and executing the original search strategy. We also acknowledge Micere Thuku, Jordi Pardo, Lara Maxwell, and the Cochrane Musculoskeletal Group for their ongoing support and their help with the preparation of this manuscript.

Footnotes

  • This report is based on a Cochrane review published in The Cochrane Library 2013, Issue 5 (see www.thecochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library should be consulted for the most recent version of the review.

  • Accepted for publication January 31, 2014.

REFERENCES

  1. 1.↵
    1. Kremer J
    . The changing face of therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:845–52.
    OpenUrlPubMed
  2. 2.↵
    1. Felson D,
    2. Anderson J,
    3. Meenan R
    . The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990;33:1449–61.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Suarez-Almazor ME,
    2. Belseck E,
    3. Shea B,
    4. Wells G,
    5. Tugwell P
    . Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2):CD000957.
  4. 4.↵
    1. Tugwell P,
    2. Bennett K,
    3. Gent M
    . Methotrexate in rheumatoid arthritis. Ann Intern Med 1987;107:358–66.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Schnabel A,
    2. Gross WL
    . Low-dose methotrexate in rheumatic diseases — efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994;23:310–27.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Leeb BF,
    2. Witzmann G,
    3. Ogris E,
    4. Studnicka-Benke A,
    5. Andel I,
    6. Schweitzer H,
    7. et al.
    Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459–63.
    OpenUrlPubMed
  7. 7.↵
    1. Griffith S,
    2. Fisher J,
    3. Clarke S,
    4. Montgomery B,
    5. Jones P,
    6. Saklatvala J,
    7. et al.
    Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000;39:1102–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Joyce D,
    2. Will D,
    3. Hoffman D,
    4. Laing B,
    5. Blackbourn S
    . Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913–4.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Tishler M,
    2. Caspi D,
    3. Fishel B,
    4. Yaron M
    . The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988;31:906–8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Arnett F,
    2. Edworthy S,
    3. Bloch D,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Higgins JPT,
    2. Green S
    . Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed March 5, 2014.] Available from: www.cochrane-handbook.org
  12. 12.↵
    1. Chakravarty K,
    2. McDonald H,
    3. Pullar T,
    4. Taggart A,
    5. Chalmers R,
    6. Oliver S,
    7. et al.
    BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008; 47:924–5.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Dutch Society of Rheumatology
    . Guidelines for medication: methotrexate ID – 52, 2009 [in Dutch]. [Internet. Accessed March 5, 2014.] Available from: www.nvrnl/richtlijnen/Totstandkoming_richtlijnen
  14. 14.↵
    1. GUIPCAR Group
    . Clinical practice guideline for the management of rheumatoid arthritis in Spain, ID - 54. Madrid: Spanish Society of Rheumatology;2007.
  15. 15.↵
    1. Singh JA,
    2. Furst DE,
    3. Bharat A,
    4. Curtis JR,
    5. Kavanaugh AF,
    6. Kremer JM,
    7. et al.
    2012 Update of the 2008 American College of Rheumatology Recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625–39.
    OpenUrlCrossRef
  16. 16.↵
    1. Higgins J,
    2. Altman D
    . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed March 5, 2014.] Available from: www.cochrane-handbook.org
  17. 17.↵
    1. Schünemann HJ,
    2. Oxman AD,
    3. Higgins JPT,
    4. Vist GE,
    5. Glasziou P,
    6. Guyatt GH
    . Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed March 5, 2014.] Available from: www.cochrane-handbook.org
  18. 18.↵
    1. Schünemann HJ,
    2. Oxman AD,
    3. Vist G,
    4. Higgins J,
    5. Deeks JJ,
    6. Glasziou P,
    7. et al.
    Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed March 5, 2014.] Available from: www.cochrane-handbook.org
  19. 19.↵
    1. Buckley L,
    2. Vacek P,
    3. Cooper S
    . Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990;17:1158–61.
    OpenUrlPubMed
  20. 20.↵
    1. Morgan SL,
    2. Baggott J,
    3. Vaughn W,
    4. Young P,
    5. Austin J,
    6. Krumdieck C,
    7. et al.
    The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9–18.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Morgan SL,
    2. Baggot JE,
    3. Vaughn WH,
    4. Austin JS,
    5. Veitch JA,
    6. Lee JY,
    7. et al.
    Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo controlled trial. Ann Intern Med 1994;121:833–41.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Shiroky JB,
    2. Neville C,
    3. Esdaile JM,
    4. Choquette D,
    5. Zummer M,
    6. Hazeltine M,
    7. et al.
    Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795–803.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Van Ede A,
    2. Laan R,
    3. Blom H,
    4. Huizinga T,
    5. Haagsma C,
    6. Giesendorf B,
    7. et al.
    The C677T mutation in the methylenetetrahydrofolate reductase gene. A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525–30.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Weinblatt ME,
    2. Maier AL,
    3. Coblyn JS
    . Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993;20:950–2.
    OpenUrlPubMed
  25. 25.↵
    Methotrexate — clinical pharmacology (updated 2013). [Internet. Accessed March 31, 2014.] Available from: www.drugs.com/pro/methotrexate.html
  26. 26.↵
    1. Dijkmans B
    . Folate supplementation and methotrexate. Br J Rheumatol 1995;34:1172–4.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Furst DE,
    2. Clements PJ
    . Pharmacologic approaches. SAARDs II. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1994: section 8, chapter 13, pp.1–8.
  28. 28.↵
    1. Drummond M,
    2. Bosi Ferraz M,
    3. Mason J
    . Assessing the cost effectiveness of NSAID: an international perspective. J Rheumatol 1995;22:1408–14.
    OpenUrlPubMed
  29. 29.↵
    1. Morgan S,
    2. Alarcón G,
    3. Krumdieck C
    . Folic acid supplementation during methotrexate therapy: it makes sense (editorial). J Rheumatol 1993;20:929–30.
    OpenUrlPubMed
  30. 30.↵
    1. Salach R,
    2. Cash J
    . Methotrexate: The emerging drug of choice for serious rheumatoid arthritis. Clin Ther 1994;16:912–22.
    OpenUrlPubMed
  31. 31.↵
    1. Hartman M,
    2. van Ede AE,
    3. Severens JL,
    4. Laan RF,
    5. van de Putte L,
    6. van der Wilt GJ
    . Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. J Rheumatol 2004;31:902–8.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 6
1 Jun 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis
Beverley Shea, Michael V. Swinden, Elizabeth Tanjong Ghogomu, Zulma Ortiz, Wanruchada Katchamart, Tamara Rader, Claire Bombardier, George A. Wells, Peter Tugwell
The Journal of Rheumatology Jun 2014, 41 (6) 1049-1060; DOI: 10.3899/jrheum.130738

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Folic Acid and Folinic Acid for Reducing Side Effects in Patients Receiving Methotrexate for Rheumatoid Arthritis
Beverley Shea, Michael V. Swinden, Elizabeth Tanjong Ghogomu, Zulma Ortiz, Wanruchada Katchamart, Tamara Rader, Claire Bombardier, George A. Wells, Peter Tugwell
The Journal of Rheumatology Jun 2014, 41 (6) 1049-1060; DOI: 10.3899/jrheum.130738
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

RHEUMATOID ARTHRITIS
COCHRANE REVIEW
FOLIC ACID
FOLINIC ACID

Related Articles

Cited By...

More in this TOC Section

  • Restoring Balance: Immune Tolerance in Rheumatoid Arthritis
  • Osteolysis in Systemic Sclerosis: A Scoping Review
  • The Role of Complement in Autoimmune Disease-Associated Thrombotic Microangiopathy and the Potential for Therapeutics
Show more Review

Similar Articles

Keywords

  • rheumatoid arthritis
  • COCHRANE REVIEW
  • FOLIC ACID
  • FOLINIC ACID

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire